|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braunstein LZ and Taghian AG: Molecular
phenotype: Multigene assays, and the locoregional management of
breast cancer. Semin Radiat Oncol. 26:9–16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jhan JR and Andrechek ER: Triple-negative
breast cancer and the potential for targeted therapy.
Pharmacogenomics. 18:1595–1609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
EL Baiomy MA and El Kashef WF: ERCC1
expression in metastatic triple negative breast cancer patients
treated with platinum-based chemotherapy. Asian Pac J Cancer Pre.
18:507–513. 2017.
|
|
5
|
Kim KH, Do IG, Kim HS, Chang MH, Kim HS,
Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, et al: Excision repair
cross-complementation group 1 (ERCC1) expression in advanced
urothelial carcinoma patients receiving cisplatin-based
chemotherapy. APMIS. 118:941–948. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bepler G, Williams C, Schell MJ, Chen W,
Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, et al:
Randomized international phase III trial of ERCC1 and RRM1
expression-based chemotherapy versus gemcitabine/carboplatin in
advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gong W, Zhang X, Wu J, Chen L, Li L, Sun
J, Lv Y, Wei X, Du Y, Jin H and Dong J: RRM1 expression and
clinical outcome of gemcitabine-containing chemotherapy for
advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer.
75:374–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamath K, Wilson L, Cabral F and Jordan
MA: BetaIII-tubulin induces paclitaxel resistance in association
with reduced effects on microtubule dynamic instability. J Biol
Chem. 280:12902–12907. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Narvi E, Jaakkola K, Winsel S,
Oetken-Lindholm C, Halonen P, Kallio L and Kallio MJ: Altered TUBB3
expression contributes to the epothilone response of mitotic cells.
Br J Cancer. 15:82–90. 2013. View Article : Google Scholar
|
|
10
|
Shan F, Liu YL, Wang Q and Shi YL:
Thymidylate synthase predicts poor response to pemetrexed
chemotherapy in patients with advanced breast cancer. Oncol Lett.
16:3274–3280. 2018.PubMed/NCBI
|
|
11
|
Gao Y, Cui J, Xi H, Cai A, Shen W, Li J,
Zhang K, Wei B and Chen L: Association of thymidylate synthase
expression and clinical outcomes of gastric cancer patients treated
with fluoropyrimidine-based chemotherapy: A meta-analysis. Onco
Targets Ther. 9:1339–1350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brase JC, Schmidt M, Fischbach T, Sültmann
H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG and
Gehrmann MC: ERBB2 and TOP2A in breast cancer: A comprehensive
analysis of gene amplification, RNA levels, and protein expression
and their influence on prognosis and prediction. Clin Cancer Res.
16:2391–2401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Malley FP, Chia S, Tu D, Shepherd LE,
Levine MN, Huntsman D, Bramwell VH, Andrulis IL and Pritchard KI:
Topoisomerase II alpha protein and responsiveness of breast cancer
to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG
randomized MA.5 adjuvant trial. Breast Cancer Res Treat.
128:401–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang C, Zhou Q, He J, Yang H, Luo X and Xu
J: Application of multiplex branched DNA liquidchip technology
(mbl) for optimal selection of chemotherapy in elderly patients. J
Geriatr Oncol. 5:S142014. View Article : Google Scholar
|
|
15
|
Han Y, Li G, Su C, Ren H, Chu X, Zhao Q,
Zhu Y, Wang Z, Hu B, An G, et al: Exploratory study on the
correlation between 14 lung cancer-related gene expression and
specific clinical characteristics of NSCLC patients. Mol Clin
Oncol. 1:887–893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS,
Shan B and Zhang L: Tumor gene mutations and messenger RNA
expression: Correlation with clinical response to icotinib
hydrochloride in non-small cell lung cancer. Chin Med J (Engl).
124:19–25. 2011.PubMed/NCBI
|
|
17
|
Sun S, Shi W, Wu Z, Zhang G, Yang BO and
Jiao S: Prognostic significance of the mRNA expression of ERCC1,
RRM1, TUBB3 and TYMS genes in patients with non-small cell lung
cancer. Exp Ther Med. 10:937–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chinese Anti-Cancer Association, Committee
of Breast Cancer Society. Guideline for diagnosis and treatment of
breast cancer (version 2011). China Oncol. 27:695–759. 2011.(In
Chinese).
|
|
20
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
21
|
Croteau DL, Peng Y and Van Houten B: DNA
repair gets physical: Mapping an XPA-binding site on ERCC1. DNA
Repair (Amst). 7:819–826. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC,
Kim JS and Kim HJ: Prognostic value of expression of ERCC1,
thymidylate synthase, and glutathione S-transferase P1 for
5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Ann Oncol. 18:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee
JH, Roh MS, Kim DC, Park KJ, Choi HJ and Kim HJ: Prognostic value
of ERCC1, thymidylate synthase, and glutathione S-transferase pi
for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am
J Clin Oncol. 32:38–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J,
Lee S, Kim J, Shim YM, Ahn JS and Park K: ERCC1 expression as a
prognostic marker in N2(+) nonsmall-cell lung cancer patients
treated with platinum-based neoadjuvant concurrent
chemoradiotherapy. Cancer. 113:1379–1386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herrick J and Sclavi B: Ribonucleotide
reductase and the regulation of DNA replication: An old story and
an ancient heritage. Mol Microbiol. 63:22–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katsetos CD, Herman MM and Mörk SJ: Class
III beta-tubulin in human development and cancer. Cell Motil
Cytoskeleton. 55:77–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Wu J, Lu H, Huang O and Shen K:
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological
complete remission predictive accuracy in breast cancer. Cancer
Sci. 103:262–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Sparano JA, Fineberg S, Stead L,
Sunkara J, Horwitz SB and McDaid HM: High expression of class III
β-tubulin predicts good response to neoadjuvant taxane and
doxorubicin/cyclophosphamide-based chemotherapy in estrogen
receptor-negative breast cancer. Clin Breast Cancer. 13:103–108.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sève P and Dumontet C: Is class III
beta-tubulin a predictive factor in patients receiving
tubulin-binding agents? Lancet Oncol. 9:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kakimoto M, Uetake H, Osanai T, Shirota Y,
Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV and
Sugihara K: Thymidylate synthase and dihydropyrimidine
dehydrogenase gene expression in breast cancer predicts 5-FU
sensitivity by a histocultural drug sensitivity test. Cancer Lett.
223:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Soong R, Shah N, Salto-Tellez M, Tai BC,
Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al: Prognostic
significance of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase protein expression in
colorectal cancer patients treated with or without
5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shintani Y, Ohta M, Hirabayashi H, Tanaka
H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S and Matsuda H:
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA
levels in tumor tissues and the efficacy of 5-fluorouracil in
patients with non-small-cell lung cancer. Lung Cancer. 45:189–196.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jacot W, Fiche M, Zaman K, Wolfer A and
Lamy PJ: The HER2 amplicon in breast cancer: Topoisomerase IIA and
beyond. Biochim Biophys Acta. 1836:146–157. 2013.PubMed/NCBI
|
|
36
|
Moretti E, Desmedt C, Biagioni C, Regan
MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou
C, Rimm DL and Di Leo A: TOP2A protein by quantitative
immunofluorescence as a predictor of response to epirubicin in the
neoadjuvant treatment of breast cancer. Future Oncol. 9:1477–1487.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han Y, Wang XB, Xiao N and Liu ZD: mRNA
expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS
and TUBB3 in postoperative patients with non-small cell lung
cancer. Asian Pac J Cancer Prev. 14:2987–2990. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang
L, Zheng X and Jiang J: Expression of ERCC1, TYMS, TUBB3, RRM1 and
TOP2A in patients with esophageal squamous cell carcinoma: A
hierarchical clustering analysis. Exp Ther Med. 7:1578–1582. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang
J, Lv M, Zhang J and Zhou C: ERCC1, RRM1 and BRCA1 mRNA expression
levels and clinical outcome of advanced non-small cell lung cancer.
Med Oncol. 28:1411–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao H, Zhang H, Du Y and Gu X: Prognostic
significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with
advanced non-small cell lung cancer receiving chemotherapy. Tumour
Biol. 35:12679–12688. 2014. View Article : Google Scholar : PubMed/NCBI
|
